US 11,807,627 B2
Morphic forms of complement factor D inhibitors
Avinash Phadke, Branford, CT (US); Akihiro Hashimoto, Branford, CT (US); and Mark Andres, Bend, OR (US)
Assigned to Achillon Pharmaceuticals, Inc., Boston, MA (US)
Appl. No. 17/279,767
Filed by Achillion Pharmaceuticals, Inc., Blue Bell, PA (US)
PCT Filed Sep. 25, 2019, PCT No. PCT/US2019/053012
§ 371(c)(1), (2) Date Mar. 25, 2021,
PCT Pub. No. WO2020/069024, PCT Pub. Date Apr. 2, 2020.
Claims priority of provisional application 62/796,776, filed on Jan. 25, 2019.
Claims priority of provisional application 62/760,520, filed on Nov. 13, 2018.
Claims priority of provisional application 62/757,565, filed on Nov. 8, 2018.
Claims priority of provisional application 62/736,294, filed on Sep. 25, 2018.
Prior Publication US 2021/0332026 A1, Oct. 28, 2021
Int. Cl. C07D 401/14 (2006.01)
CPC C07D 401/14 (2013.01) [C07B 2200/13 (2013.01)] 20 Claims
 
1. An isolated crystalline form of Compound 3:

OG Complex Work Unit Chemistry
wherein the isolated crystalline form is:
Form B, characterized by a powder X-ray diffraction (PXRD) pattern comprising at least three 2theta values selected from 16.2±0.4°, 15.7±0.4°, 4.5±0.4°, 22.6±0.4°, 17.4±0.4°, 22.0±0.4°, 8.3±0.4°, 16.1±0.4°, 21.1±0.4°, 18.7±0.4°, 18.3±0.4°, 23.9±0.4°, and 27.5±0.4°; or
Form A, characterized by a powder X-ray diffraction (PXRD) pattern comprising at least one 2theta values selected from 2.6±0.4°, 3.6±0.4°, and 3.8±0.4°; or
Form M, characterized by a powder X-ray diffraction (PXRD) pattern comprising at least three 2theta values selected from 15.0±0.4°, 7.5±0.4°, 23.8±0.4°, 7.2±0.4°, 19.1±0.4°, 5.2±0.4°, 8.3±0.4°, 26.2±0.4°, 22.8±0.4°, 21.7±0.4°, and 24.9±0.4°.